Valneva’s vaccine for chikungunya, a mosquito-borne virus that creates symptoms comparable to dengue and Zika, has demonstrated positive results in a late-stage clinical trial according to The Lancet. Valneva used a less potent form of the virus in the vaccine, which was given to 3,082 of the 4,115 healthy adults enrolled in the trial across the US. The company reported that there were no causes for concern over the vaccine’s safety profile, with minor side effects including headaches, fatigue, muscle and joint pain, and discomfort at the injection site. The immune responses to the vaccine were ambitious, with 99% of participants testing positive for antibodies to fight the infection 28 days after vaccination. A follow-up study is already underway to test the vaccine’s effectiveness over a longer time period of up to five years, as the vaccine is intended to guard against chikungunya epidemics caused by the virus in the wild rather than in laboratory-controlled circumstances.
Denial of responsibility! TechCodex is an automatic aggregator of the all world’s media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, and all materials to their authors. For any complaint, please reach us at – [email protected]. We will take necessary action within 24 hours.
Jessica Irvine is a tech enthusiast specializing in gadgets. From smart home devices to cutting-edge electronics, Jessica explores the world of consumer tech, offering readers comprehensive reviews, hands-on experiences, and expert insights into the coolest and most innovative gadgets on the market.
